Elham Mousavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elham Mousavi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Samarbaf-Zadeh
Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 shared publications Saeedeh Ebrahimi
Department of Medical Microbiology (Bacteriology and Virology), Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
4 shared publications- Shokouh Ghafari
Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
4 shared publications - Zahra Arab-Bafrani
Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4 shared publications Ali Teimoori
Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3 shared publicationsElham Heidari
Department of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran
3 shared publications
Latest Publications
- Open Access
- 19 October 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102311
Investigation of Epstein-Barr virus coinfection and changes in the gene expression of angiotensin converting enzyme II in peripheral blood mononuclear cells in COVID-19 patients
- 19 October 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 44, 102311
Open AccessInvestigation of Epstein-Barr virus coinfection and changes in the gene expression of angiotensin converting enzyme II in peripheral blood mononuclear cells in COVID-19 patients
- Open Access
- 1 December 2024
- Published by Wolters Kluwer Health in Journal of Acute Disease
- Vol. 13 (6) , 199-207
Risk factors associated with mortality among vaccinated COVID-19 patients: A retrospective study
Objective: To explore the underlying causes of death among vaccinated COVID-19 patients. Methods: The medical record of COVID-19 patients admitted to the main COVID-19 referral center in southeast Iran from January to March 2022 was investigated. Then, risk factors for mortality were statistically assessed. Results: 92 patients were included, with 50 in infectious disease ward and 42 in ICU ward. In total, 37% of patients succumbed to COVID-19. The median age of those who died was 69.9 years. Dementia and genitourinary system-related diseases was associated with an increased risk of death [6.00 (95% CI: 1.14-31.66) and 4.93 (95% CI: 1.80-13.52)]. Furthermore, the elevated levels of white blood cells, neutrophils, lactate dehydrogenase, blood urea nitrogen, and creatinine were associated with an increased risk of death by 4.93 (95% CI: 1.82-13.36), 16.57 (95% CI: 2.10-131.31), 3.23 (95% CI: 1.15-9.03), 4.48 (95% CI: 1.78-11.31), and 4.27 (95% CI: 1.49-12.22), respectively. Conclusions: Despite receiving the SARS-CoV-2 vaccine, individuals who suffer from dementia and genitourinary system-related diseases are at risk of death with new strains of SARS-CoV-2 infection. Furthermore, the increase of white blood cell, neutrophils, lactate dehydrogenase, blood urea nitrogen, and creatinine in patients’ blood can be considered as warning indicators of disease progression and death.
- 1 December 2024
- Published by Wolters Kluwer Health in Journal of Acute Disease
- Vol. 13 (6) , 199-207
Open AccessRisk factors associated with mortality among vaccinated COVID-19 patients: A retrospective study
Objective: To explore the underlying causes of death among vaccinated COVID-19 patients. Methods: The medical record of COVID-19 patients admitted to the main COVID-19 referral center in southeast Iran from January to March 2022 was investigated. Then, risk factors for mortality were statistically assessed. Results: 92 patients were included, with 50 in infectious disease ward and 42 in ICU ward. In total, 37% of patients succumbed to COVID-19. The median age of those who died was 69.9 years. Dementia and genitourinary system-related diseases was associated with an increased risk of death [6.00 (95% CI: 1.14-31.66) and 4.93 (95% CI: 1.80-13.52)]. Furthermore, the elevated levels of white blood cells, neutrophils, lactate dehydrogenase, blood urea nitrogen, and creatinine were associated with an increased risk of death by 4.93 (95% CI: 1.82-13.36), 16.57 (95% CI: 2.10-131.31), 3.23 (95% CI: 1.15-9.03), 4.48 (95% CI: 1.78-11.31), and 4.27 (95% CI: 1.49-12.22), respectively. Conclusions: Despite receiving the SARS-CoV-2 vaccine, individuals who suffer from dementia and genitourinary system-related diseases are at risk of death with new strains of SARS-CoV-2 infection. Furthermore, the increase of white blood cell, neutrophils, lactate dehydrogenase, blood urea nitrogen, and creatinine in patients’ blood can be considered as warning indicators of disease progression and death.
- 8 November 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (30) , 1-12
Exploring potential of graphene oxide as an alternative antiviral approach for influenza A H1N1
Aim: Graphene oxide (GO), known for its distinctive physicochemical properties, shows promise as a nanomaterial capable of combating infectious agents. This study investigates the efficacy of GO nanoparticles in restricting influenza A H1N1 replication in MDCK cells.Methods: GO nanoparticles were synthesized. After evaluating the toxicity of GO nanoparticles, the antiviral activity of the highest nontoxic concentration of GO against influenza A H1N1 in MDCK cells was studied.Results: GO treatments resulted in substantial decreases in virus titers, as shown via hemagglutination assay, TCID50 assay and real-time PCR analysis.Conclusion: This study emphasizes that GO nanoparticles have a high level of effectiveness against influenza A H1N1 viruses, making them an intriguing option for various antiviral uses.
- 8 November 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (30) , 1-12
Exploring potential of graphene oxide as an alternative antiviral approach for influenza A H1N1
Aim: Graphene oxide (GO), known for its distinctive physicochemical properties, shows promise as a nanomaterial capable of combating infectious agents. This study investigates the efficacy of GO nanoparticles in restricting influenza A H1N1 replication in MDCK cells.Methods: GO nanoparticles were synthesized. After evaluating the toxicity of GO nanoparticles, the antiviral activity of the highest nontoxic concentration of GO against influenza A H1N1 in MDCK cells was studied.Results: GO treatments resulted in substantial decreases in virus titers, as shown via hemagglutination assay, TCID50 assay and real-time PCR analysis.Conclusion: This study emphasizes that GO nanoparticles have a high level of effectiveness against influenza A H1N1 viruses, making them an intriguing option for various antiviral uses.
- Open Access
- 1 October 2024
- Published by Medknow in Journal of Acute Disease
- Vol. 13 (5) , 173-178
Changes in the gene expression of activation-induced cytidine deaminase in peripheral blood mononuclear cells in COVID-19 patients
Objective: To assess the changes in gene expression of activation- induced cytidine deaminase (AID) in COVID-19 patients and its relationship with the presence of autoantibodies in those ones. Methods: This retrospective study was carried out among COVID-19 patients’ serum and peripheral blood mononuclear cells that were archived at the main COVID-19 referral centers in Iran from January to March 2022. The titer of autoantibodies in the serum of healthy and COVID-19 subjects was investigated by serological tests. Then, the AID gene expression in peripheral blood mononuclear cells in two groups was evaluated using the real-time polymerase chain reaction method. Results: 100 patients were included. In total, 8% and 1% of patients had a significant titer of anti-citruhinated protein antibody and antinuclear antibody autoantibodies, respectively, and those suffered from at least one comorbidity. No patient was positive for antiphospholipid autoantibody. Moreover, no significant changes were observed in the titer of autoantibodies between healthy subjects and patients. Furthermore, the increase in the expression of the AID gene was not significant in two groups. Conclusions: The presence of autoantibodies in COVID-19 patients might be linked to the previous underlying disease.
- 1 October 2024
- Published by Medknow in Journal of Acute Disease
- Vol. 13 (5) , 173-178
Open AccessChanges in the gene expression of activation-induced cytidine deaminase in peripheral blood mononuclear cells in COVID-19 patients
Objective: To assess the changes in gene expression of activation- induced cytidine deaminase (AID) in COVID-19 patients and its relationship with the presence of autoantibodies in those ones. Methods: This retrospective study was carried out among COVID-19 patients’ serum and peripheral blood mononuclear cells that were archived at the main COVID-19 referral centers in Iran from January to March 2022. The titer of autoantibodies in the serum of healthy and COVID-19 subjects was investigated by serological tests. Then, the AID gene expression in peripheral blood mononuclear cells in two groups was evaluated using the real-time polymerase chain reaction method. Results: 100 patients were included. In total, 8% and 1% of patients had a significant titer of anti-citruhinated protein antibody and antinuclear antibody autoantibodies, respectively, and those suffered from at least one comorbidity. No patient was positive for antiphospholipid autoantibody. Moreover, no significant changes were observed in the titer of autoantibodies between healthy subjects and patients. Furthermore, the increase in the expression of the AID gene was not significant in two groups. Conclusions: The presence of autoantibodies in COVID-19 patients might be linked to the previous underlying disease.
- Open Access
- 22 November 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-5
Toll-like receptor 7 and RIG-I-like receptors expression in peripheral blood mononuclear cells of naïve patients with hepatitis C
The proper function of Pattern Recognition Receptors (PRRs) as a part of the host immune system can eliminate numerous pathogens from the body. However, some viruses can manipulate PRRs to escape the innate immune system. As there is controversy in the activation of PRRs in patients infected with HCV, we decided to evaluate the gene expression changes of PRRs in HCV cases compared to the healthy control. In this study, the relative expression of Toll-like receptor 7, RIG-I, and MAD-5 in peripheral mononuclear blood cells of twenty HCV patients and twenty healthy controls of the same gender and age were analyzed by quantitative Real-time PCR. Our results showed that the expression of RIG-I and MAD-5 significantly increased in HCV-infected samples compared to the controls (P value:0.01; P value:0.05), while the expression of TLR7 was similar between the case and the control group (P value:0.1). It seems in suppressing HCV, RIG-I and MAD-5 receptors are likely to be more activated than TRL7 in HCV patients. The lack of TLR7 gene expression might reflect the defect of the host in the stimulation of the innate immune system through the TLR7 pathway.
- 22 November 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-5
Open AccessToll-like receptor 7 and RIG-I-like receptors expression in peripheral blood mononuclear cells of naïve patients with hepatitis C
The proper function of Pattern Recognition Receptors (PRRs) as a part of the host immune system can eliminate numerous pathogens from the body. However, some viruses can manipulate PRRs to escape the innate immune system. As there is controversy in the activation of PRRs in patients infected with HCV, we decided to evaluate the gene expression changes of PRRs in HCV cases compared to the healthy control. In this study, the relative expression of Toll-like receptor 7, RIG-I, and MAD-5 in peripheral mononuclear blood cells of twenty HCV patients and twenty healthy controls of the same gender and age were analyzed by quantitative Real-time PCR. Our results showed that the expression of RIG-I and MAD-5 significantly increased in HCV-infected samples compared to the controls (P value:0.01; P value:0.05), while the expression of TLR7 was similar between the case and the control group (P value:0.1). It seems in suppressing HCV, RIG-I and MAD-5 receptors are likely to be more activated than TRL7 in HCV patients. The lack of TLR7 gene expression might reflect the defect of the host in the stimulation of the innate immune system through the TLR7 pathway.
- 1 June 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 152, 135-145
The most effective polymorphisms of paraoxonase-1 gene on enzyme activity and concentration of paraoxonase-1 protein in type 2 diabetes mellitus patients and non-diabetic individuals: A systematic review and meta-analysis
- 1 June 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 152, 135-145
The most effective polymorphisms of paraoxonase-1 gene on enzyme activity and concentration of paraoxonase-1 protein in type 2 diabetes mellitus patients and non-diabetic individuals: A systematic review and meta-analysis
- 1 June 2019
- Published by Elsevier in European Polymer Journal
- Vol. 115, 115-124
Multi-cellular tumor spheroids formation of colorectal cancer cells on Gelatin/PLCL and Collagen/PLCL nanofibrous scaffolds
- 1 June 2019
- Published by Elsevier in European Polymer Journal
- Vol. 115, 115-124
Multi-cellular tumor spheroids formation of colorectal cancer cells on Gelatin/PLCL and Collagen/PLCL nanofibrous scaffolds
- 14 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 8192-8202
The most reliable surface marker for the identification of colorectal cancer stem‐like cells: A systematic review and meta‐analysis
Several surface markers have been proposed for the identification and characterization of colorectal cancer stem‐like cells (CR‐CSLCs). However, their reliability in CR‐CSLCs identification remains controversial. This study evaluated the correlation between all candidate surface marker's expression and CSLCs properties (tumorigenicity) through monitoring in vivo tumor incidence and final tumor volume. PubMed, Web of Science, and Scopus databases were systematically searched until November 2017. A total of 27 studies were found that met the inclusion criteria for cluster of differentiation 133 (CD133) and CD44 markers. Results indicated that either CD133 or CD44 positive cells caused about twofold increase in tumor volume compared with the negative cells (p < 0.05). In two groups of cells derived from primary tumors and cell lines, CD133 + cells had 25 and 1.45 times higher tumor incidence potential than CD133 − cells, respectively ( p < 0.05). Also, cohort evaluation showed that CD133 overexpression at protein level is a marker of poor overall survival in colorectal cancer (CRC) patients. While CD44 + cells displayed twofold tumorigenicity compared with the negative cells ( p < 0.05), combination of CD44 and CD133 showed about sevenfold tumorigenicity potential ( p < 0.05). In conclusion, the present meta‐analysis suggests that CD133 is a robust biomarker to identify primary tumor CSLCs and can be proposed as a prognostic marker of CRC patient whereas it should be used with caution in cell lines. It seems to be more reliable to use CD133 in combination with CD44 as target biomarkers for the isolation of CR‐CSLCs in both cell line and primary tumor cells populations.
- 14 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 8192-8202
The most reliable surface marker for the identification of colorectal cancer stem‐like cells: A systematic review and meta‐analysis
Several surface markers have been proposed for the identification and characterization of colorectal cancer stem‐like cells (CR‐CSLCs). However, their reliability in CR‐CSLCs identification remains controversial. This study evaluated the correlation between all candidate surface marker's expression and CSLCs properties (tumorigenicity) through monitoring in vivo tumor incidence and final tumor volume. PubMed, Web of Science, and Scopus databases were systematically searched until November 2017. A total of 27 studies were found that met the inclusion criteria for cluster of differentiation 133 (CD133) and CD44 markers. Results indicated that either CD133 or CD44 positive cells caused about twofold increase in tumor volume compared with the negative cells (p < 0.05). In two groups of cells derived from primary tumors and cell lines, CD133 + cells had 25 and 1.45 times higher tumor incidence potential than CD133 − cells, respectively ( p < 0.05). Also, cohort evaluation showed that CD133 overexpression at protein level is a marker of poor overall survival in colorectal cancer (CRC) patients. While CD44 + cells displayed twofold tumorigenicity compared with the negative cells ( p < 0.05), combination of CD44 and CD133 showed about sevenfold tumorigenicity potential ( p < 0.05). In conclusion, the present meta‐analysis suggests that CD133 is a robust biomarker to identify primary tumor CSLCs and can be proposed as a prognostic marker of CRC patient whereas it should be used with caution in cell lines. It seems to be more reliable to use CD133 in combination with CD44 as target biomarkers for the isolation of CR‐CSLCs in both cell line and primary tumor cells populations.
- 3 October 2018
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 107 (4) , 1264-1271
Using of keratin substrate for enrichment of HT29 colorectal cancer stem‐like cells
Eradication of cancer stem‐like cells (CSLCs) are becoming increasingly an important target for new cancer therapies. The ability to study their behavior in vitro will provide the opportunity for high‐throughput testing of more effective treatments. In this study, spheroid‐like structures’ formation and enrichment of HT29 CSLCs were evaluated on a wool keratin‐based substrate as a bio‐mimic of natural extracellular matrix (ECM) proteins. The results indicated that culturing on keratin substrate increased spheroid formation ability and radio‐/chemoresistance of HT29 cells. Moreover, cell surface expression of CD133 CSLCs’ marker and the mRNA level of stemness genes such as Nanog, Oct4, and c‐MYC were increased. These data suggest that keratin can potentially be used for spheroid‐like structure formation and enrichment of HT29 CSLCs. In addition, it seems that the induction of stemness characteristics on keratin substrate is probably because of the activation of α2β1 integrin signaling pathway. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 1264–1271, 2019.
- 3 October 2018
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 107 (4) , 1264-1271
Using of keratin substrate for enrichment of HT29 colorectal cancer stem‐like cells
Eradication of cancer stem‐like cells (CSLCs) are becoming increasingly an important target for new cancer therapies. The ability to study their behavior in vitro will provide the opportunity for high‐throughput testing of more effective treatments. In this study, spheroid‐like structures’ formation and enrichment of HT29 CSLCs were evaluated on a wool keratin‐based substrate as a bio‐mimic of natural extracellular matrix (ECM) proteins. The results indicated that culturing on keratin substrate increased spheroid formation ability and radio‐/chemoresistance of HT29 cells. Moreover, cell surface expression of CD133 CSLCs’ marker and the mRNA level of stemness genes such as Nanog, Oct4, and c‐MYC were increased. These data suggest that keratin can potentially be used for spheroid‐like structure formation and enrichment of HT29 CSLCs. In addition, it seems that the induction of stemness characteristics on keratin substrate is probably because of the activation of α2β1 integrin signaling pathway. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 1264–1271, 2019.